At a glance

Why are BPC-157 and TB-500 paired?

BPC-157 and TB-500 are commonly paired in reported recovery protocols, because each has been studied separately for tissue repair¹. Most published findings on both peptides come from laboratory and animal research², and controlled human evidence for injury recovery¹ is lacking.

• BPC-157: A systematic review³ found BPC-157 improved functional, structural, and biomechanical outcomes in animal muscle, tendon, ligament, and bone injuries.
• TB-500: A synthetic, acetylated (chemically modified) fragment of thymosin beta-4 that emerged as a veterinary preparation⁴, copying the parent protein's region tied to actin binding and wound repair. Animal research on full-length thymosin beta-4⁵ informs interest in TB-500, a distinct fragment¹.

Why is it called the Wolverine stack?

BPC-157 and TB-500 used together are often called the "Wolverine stack." The nickname comes from Wolverine, the X-Men character known for superhuman healing, and reflects the pairing's reputation⁶ for faster healing and less inflammation. It's a marketing name rather than a scientific term. The pairing has grown popular among athletes, bodybuilders, and people interested in healthy aging, and it is sold online under that name.

Has research tested BPC-157 and TB-500 together?

One controlled study has tested BPC-157 and TB-500 together, in 32 rats after Achilles tendon repair⁷. Rats got BPC-157, TB-500, both, or neither by intraperitoneal injection (into the abdominal cavity) for four weeks.

Both peptides were linked with better tendon structure and collagen organization. TB-500 alone also made the repaired tendon significantly stronger. The combination improved tendon structure, with no added benefit over either peptide alone. The authors call the work exploratory and both peptides worth further study in tendon repair.

In one clinic's knee injection chart review⁸, 3 of 4 people given BPC-157 with thymosin beta-4, TB-500's parent protein, reported significant improvement. A three-patient report on lower-jaw nerve injury⁹ gave BPC-157 and TB-500 with another peptide, a steroid, and a local anesthetic. All three patients showed nerve-sensation recovery during follow-up.

A registered rotator cuff repair trial¹⁰ plans to test BPC-157 alone in people.

What do reported combined protocols describe?

Reported combined protocols are practice patterns rather than a standardized dose, since no validated regimen¹ has been set for either peptide.

• Dose and schedule: No standard combined dose exists, so a prescribing clinician sets the schedule.
• Route: The rat study's intraperitoneal route⁷ does not automatically describe under-the-skin, oral, or nasal use.
• Separate vials or one blend: Reported protocols use two products or one pre-mixed vial, sometimes sold under the "Wolverine" name. No published study has tested a pre-mixed product.

Either way, product quality and health history shape safety.

Safety when combining BPC-157 and TB-500

No study has measured the safety of BPC-157 and TB-500 used together in people. For BPC-157, preclinical safety studies showed no adverse effects³, a starting point rather than a human safety profile. For TB-500, FDA has not identified any human exposure data¹¹.

Unapproved products can vary in identity, purity, concentration, sterility, and manufacturing consistency¹. FDA's stated concerns include possible immune reactions for certain routes, peptide-related impurities, and, for TB-500, potential aggregation¹¹ (clumping). Products sold online as TB-500 have not always contained what their descriptions state¹².

Reported BPC-157 side effects and TB-500 side effects come from single-peptide use.

The World Anti-Doping Agency prohibits both peptides at all times¹⁴, BPC-157 as a non-approved substance and TB-500 as a thymosin beta-4 derivative. Athletes subject to drug testing can face sanctions for using either one and should confirm current WADA and league rules first.

Getting BPC-157 and TB-500 in 2026

Superpower will offer BPC-157 and TB-500, both formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will assess whether either peptide fits a person's health care. The Superpower peptide waitlist is open now.

Neither BPC-157 nor TB-500 is an FDA-approved drug, and compounding them rests on an interim federal policy. In October 2026, the Department of Health and Human Services announced it does not intend to take enforcement action¹⁵ against state-licensed pharmacies compounding these peptides while the 503A Bulks List, the list of ingredients pharmacies may use in compounding, is finalized. The policy covers BPC-157, TB-500, and four other peptides¹⁶, with conditions that include ingredients from FDA-registered facilities and a patient-specific prescription. It followed a July 2026 FDA advisory committee recommendation to add both peptides to the list¹⁷, and that rulemaking is still underway.

About BPC-157

• BPC-157Synthetic pentadecapeptide (gastric-derived)

More answers about BPC-157